

MYCUREALL, LLC

INVESTMENT SUMMARY - April 24, 2020

This Investment Summary is neither an offer to sell nor a solicitation of an offer to buy any of these Securities. The offer is made only by the Private Placement Memorandum.

Investment Opportunity

An opportunity for accredited, high net worth and institutional investors to invest in MyCureAll, LLC ("MCA" or "the Company") a New Jersey Corporation. The Company is currently raising \$750,000 in an initial capitalization round of financing (Phase I), which the Company expects will be followed by a \$5,000,000 second round of financing (Phase II), and potentially a third round of financing (Phase III).

Phase I – Initial Capitalization - MyCureAll

The Company is raising \$750,000 in an initial round of financing to continue the development and marketing of the MyCureAll web application and MyCureAll line of CBD products. Management projects to generate revenue by the 2nd quarter of 2020. Potential investors must review full projections and footnotes (see below).

The Company is raising the capital with a convertible note offering (with conversion features at the sole discretion of the investor). The contemplated simple interest rate is estimated to be 7 percent (7%) per annum for a term of three years (3) years. The convertible feature is planned to provide investors with an option to purchase proposed future equity component at the discounted price of twenty percent (20%) of the price of the investment product in the next round of financing. They may convert all or part of their original note investment amount. They may also be allowed to invest additional funds at discount with Management's permission. The planned effective date of the proposed offering is April 15, 2020 with a closing date estimated to be September 31, 2020.

Return on Investment – **Need to Update with Combined Projections**

Based on assumptions and analysis generated by respected consultants in the healthcare technology industry, potential earnings before interest and taxes are estimated at ___% to nearly ___% of gross income, after 2020 depending on year of operation. In its first year of operation, MyCureAll expects to achieve revenues of \$432,680 (2020), \$6,090,600 (2021), \$13,589,600 (2022) and \$50,983,000 (2025). EBITDA is forecasted to be \$2,574,721 in Year 2, \$9,949,106 in Year 3 and increase to \$46,131,541 in Year 5.

Financial Projections for MyCureAll	4 States: NJ, NY, PA, and FL			33 States
	FY 2020	FY 2021	FY 2022	FY 2025
# of Patients signed up by end of year to app	200,000	5,000,000	11,000,000	25,000,000
# of recommenders signed up by end of year to app	1,000	1,500	3,000	18,000
# of dispensaries signed up by end of year to app	48	250	400	1,500
# of Providers taking CEU; includes RPh, NNP, PA, MD	0	1,200	1,800	7,000
Revenue	FY 2020	FY 2021	FY 2022	FY 2025
Subscription revenue MD	\$356,000	\$1,602,000	\$3,204,000	\$19,224,000
CEU Revenue (\$187 per CEU)		\$106,800	\$336,000	\$1,309,000
Subscription revenue dispensaries	\$55,680	\$1,575,000	\$2,520,000	\$9,450,000
Targeted marketing revenue	\$21,000	\$2,700,000	\$7,500,000	\$21,000,000
Total Revenue	\$432,680	\$5,983,800	\$13,560,000	\$50,983,000
Total Operating Expenses	\$665,254	\$3,186,079	\$3,811,894	\$4,543,459
Profit (loss) from operations	-\$357,574	\$2,574,721	\$9,949,106	\$46,131,541

The Company

MyCureAll, LLC, (MCA) is a healthcare technology company formed as a New Jersey Limited Liability Company in 2019.

Mission Statement

As experts in the pharmaceutical, social work and medical cannabis field, our mission is to properly, consistently, and effectively manage medical cannabis administration by aligning patients, doctors, dispensaries, and insurers to work hand - in - hand for safer and more effective healthcare. In providing a secure and beneficial platform for medical cannabis prescribing, our goal is to bring physical, social and financial relief from the opioid epidemic.

The Company

MyCureAll, LLC, (MCA) is a healthcare technology company formed as a New Jersey Limited Liability in 2019.

- MyCureAll is uniquely positioned at the intersection of multiple industry markets that include digital health, telemedicine, non-opioid pain treatment, cannabis, and CBD. Add
- The Co-Founders of MCA have invested \$300,00 and developed in a unique business model and building an innovative health technology platform to have medical cannabis products covered by all the major insurance carriers including workman's comp.
- Medical cannabis is a life-changing medication and for some people a life-saving medication. However, it is too expensive for most people to afford. At MyCureAll we are on a mission to enable insurance companies to pay not only for cannabis but, more importantly, the right cannabis for the right patient. With our MyCureAll app we will be able to engage the patient and doctor to make sure the patient is receiving the correct cannabis and has appropriate follow up care. Join our movement to help us get medical cannabis covered by insurance! Also sign up for our mailing list to find out when you can get your medical cannabis covered by insurance on the bottom of our website: www.mycureall.com
- This would allow for much easier access to cannabis products for patients with medical conditions at a lower cost.
- Dealing with insurance companies can be complicated, which is why MCA has assembled a team to build a technology platform to solve this problem for the Cannabis Ecosystem.

- Not only will MCA technology make access to cannabis products easier, MCA is generating a large network of patients that can be made aware of the multitude of cannabis strains and product offerings for medical conditions and increase brand awareness of cannabis companies and dispensaries that have the products available.
- This would allow for much easier access to cannabis products for patients with medical conditions at a lower cost.
- Dealing with insurance companies can be complicated, which is why MCA has assembled a team to build a technology platform to solve this problem for the Cannabis Ecosystem.
- Not only will MCA technology make access to cannabis products easier, MCA is generating a large network of patients that can be made aware of the multitude of cannabis strains and product offerings for medical conditions and increase brand awareness of cannabis companies and dispensaries that have the products available.

Cover – Slide 1

Problem – Slide 2

Medical cannabis is being established in the scientific community as a medication of choice, but the current method of prescribing cannabis is inadequate.

- Industry Bottlenecks
 - Patients spend time and money using a trial and error method to discover what cannabis strain works best to manage their symptoms.
 - Medical professionals do not know the correct strains and dosing to recommend based on the patient's qualifying condition(s).
 - Dispensaries are unable to properly manage inventory and recommend a specific strain for a patient's condition(s).
 - MAT (Medication Assisted Treatment) and Harm Reduction specialists are unable to recommend optimal dosing and strains for clients that present with comorbidities.
- The Opioid Epidemic Costs Lives and Money
 - 399,000 people died from opioid overdose from 1999 to 2017.
 - Annual deaths from opioid overdoses are "projected to reach nearly 82,000 by 2025, resulting in approximately 700,000 deaths from 2016 to 2025.
 - According to the National Institutes of Health (NIH), substance abuse costs the country over \$600 billion per year.

Solution – Slide 2

The revolutionary Patent Pending MyCureAll Web Application platform that:

- Empowers doctors to identify and prescribe specific cannabis strains based on patients' qualifying conditions
- Connects patients to recommenders, dispensaries and provides treatment plans for insurance coverage
- Allows patients to actively participate in their wellness through targeted and consistent surveys and developing a treatment plan
- Enables insurance companies to decrease overall healthcare costs while reimbursing for medical cannabis.

MyCureAll is built to serve a diverse yet connected group of clients.

1. Patients – will be able to receive the correct strain/strength for their medical condition(s), allowing for safer, more effective treatment.
2. Physicians – will receive access to standardized protocols for prescribing medical cannabis based on the patient's condition, age, sex, etc.
3. Dispensaries – will be able to better manage inventory of various cannabis strains while providing effective care based on patient needs.
4. Substance Abuse Treatment Providers – will be able to integrate medical cannabis for opioid dependent clients with MAT treatment.
5. Employers – will play an active role in providing appropriate healthcare resources to their employees.
6. Insurance Companies – will decrease spending on dangerous opioid treatments and subsequent, ineffective opioid addiction rehab programs, by providing effective cannabis usage.

Markets – Slide 3

MyCureAll is uniquely positioned at the intersection of multiple industry markets that include **Artificial Intelligence**, digital health, telemedicine, non-opioid pain treatment, cannabis and CBD.

- Artificial Intelligence for Healthcare
- Cannabis – Global
 - The global cannabis market size is projected to grow from \$10 Billion in 2018 to \$97 Billion by 2026.
 - The adoption of cannabis as a pharmaceutical product for treating medical conditions, such as cancer, arthritis, Parkinson's and Alzheimer's disease. Chronic pain among elders is expected to boost demand.
- Cannabis – United States
 - The U.S. legal cannabis sales are set to more than quintuple from \$8 billion in 2018 to \$41 billion by 2025.
 - 33 states, Washington D.C., and several territories offer medical cannabis as a legal treatment option.
- CBD
 - The global CBD market size was valued at \$3.08 billion in 2018 and is expected to reach \$22 billion by 2026.
 - Cannabidiol, also known as CBD, is among the most abundant of all the cannabinoids. It's found in all varieties of cannabis but dominates the makeup of hemp plants. Studies have shown that cannabidiol is a non-psychoactive cannabinoid, unlike THC.
 - There are scientific studies in recent years concerning CBD's medical usefulness for diseases and ailments that include pain, anxiety and depression, epilepsy, symptoms related to cancer treatment, acne and other skin issues, high blood pressure, addiction, and diabetes.
- Digital Health
 - The Digital Health market size is projected to grow from \$95 Billion in 2018 to \$509 Billion in 2029.

- Apps in smartphones make it easier for healthcare professionals to access patient information and diagnose diseases.
- Health and Medical Insurance
- Non-Opioid Pain Treatment
 - The global market size for non-opioid pain treatments should grow from \$13.8 billion in 2019 to \$31.8 billion by 2024.
 - One of the product segments for Non-opioid treatment of pain is Medical cannabis treatments. Within the segment several sub-segments are discussed as they pertain to each product segment; diseases or disorders are the basis for these sub-segments, including: Arthritis, Cancer–brain, breast, colorectal, leukemia/lymphoma, melanoma, prostate, others, Dental, Epilepsy, Fibromyalgia, Migraine, Multiple sclerosis, and surgical.
- Telehealth
- Telemedicine
 - The global telemedicine market size is expected to grow from \$24 billion in 2016 and reach \$113.1 billion by 2025

Marketing Strategy and Tactics – Slide 5

- Marketing Channels Cannabis Medical Registries
- Cannabis Partners
- Cannabis Suppliers
- If you're a supplier of medical Cannabis product such as medical marijuana or CBD, you're going to greatly benefit from aligning yourself with our cause. Unfortunately, cannabis, with its great efficacy, minimal side effects, and zero deaths, is currently very expensive for the patient. High costs are incurred not only for the actual cannabis but also in obtaining authorization by a prescriber.

Highlights

- Invested \$300K
-

Milestones

- May 2020 – Launched MyCureAll Website App
- **Date ?** – Launched MyCureAll Ecommerce website
- **Date ?** – Formulated and manufactured MyCureAll CBD line of products that include flower, tinctures, and topical salves and lotions
- **Date ?** – MCA received state clearance from Department of Health (DOH) and **Department of Insurance (DOI)** to operate in all 4 states ?
- **February 11, 2020** – Filed U.S. Provisional Application No. 62/972,756
- **January 16, 2019** – Filed U.S. Provisional Application No.: 62/793,047

MyCureAll Description

- MCA has built the MyCureAll Software-as-a-Service (“SaaS”) website and mobile application platform to assist patients, medical professionals, and dispensaries to evaluate and recommend the best cannabis strains for medical conditions.
- The MyCureAll App enables patients, physicians (prescribers) & dispensaries to work hand-in-hand to achieve a natural solution to ailments such as pain, anxiety, nausea, fibromyalgia, substance abuse, & many other conditions.
- MCA is using the advances in digital healthcare, Artificial Intelligence (AI) and blockchain technology to optimize how to find the best cannabis strain for medical conditions and accelerate the acceptance of the legal cannabis industry into the mainstream healthcare and insurance systems.
- The patent pending platform is HIPAA compliant and includes the proprietary Canna-Meter™ and Canna-Measure™ technology and next generation telemedicine technology.
- The MyCureAll App empowers insurance companies to reimburse for medical cannabis that maximizes patient outcomes, while significantly reducing overall healthcare spending by the insurance company.
- MyCureAll allows insurance companies to reimburse for medical cannabis that maximizes patient outcomes, while significantly decreasing overall spend by the insurance company.
- The MyCureAll app empowers patients to use a “one stop shopping medicinal cannabis program” to present the results of their effective strain as it relates to their qualifying condition via our patent pending technology, the Canna-Measure™. This client and meta-analysis data is shared with the patients prescriber, dispensary and insurance company via a HIPAA compliant platform. The prescriber can use the “Canna-Meter™” which offers AI technology to provide alternative strains for a client’s medical condition. Reducing the prescribers risk exposure and promoting the inventory management with the dispensary. We will increase patient compliance with symptoms assessment, prescribers reduced risk with recommendation, dispensary inventory based on their consumers purchases and interest and the insurance companies receiving a treatment plan and claim based on the client improvement.
- We manage the costs by ensuring the patients are receiving the appropriate strains of cannabis and taking the correct dose at the correct frequency for their particular indication(s).
- Cannabis will have the ability to decrease opiate overdose and death by approximately 30% compared to the normal population.
- In addition to a decrease in prescription spending as a result of cannabis, we will see a decrease in spending for treatment of pain/opioid-related issues: anxiety, depression, nausea, psychosis, sleep disorder, and seizures.
- By utilizing medical cannabis, we can also decrease how much companies spend by 50%, and more importantly, decrease morbidity and mortality by 50% as well.

MyCureAll Intellectual Property

- Canna-Meter™
 - February 11, 2020 – Filed U.S. Provisional Application No. 62/972,756
- Canna-Measure™
 - January 16, 2019 – Filed U.S. Provisional Application No.: 62/793,047

Canna-Meter™ helps everyone in the Medicinal Cannabis Ecosystem!

- Canna-Meter™ is a tool that can be used by:
 - Patients

- Doctors
- Bud Tenders
- Insurance Companies
- Canna-Meter™ can assist with:
 - Creating treatment plans for patients
 - Augmenting existing treatment plans
 - Recommending alternative strains at the dispensary during unfortunate strain shortage
 - Tool that helps you identify similar strains to your favorites to keep you at the peak of your wellness.

Canna-Measure™

- Client input the baseline of her or his symptoms and compare the post results of ingesting their prescribed Medicinal cannabis or CBD product.
- Patient can **engaged (SP)** the process of reviewing the efficacy of their medication with a scale from 1 to 100.
- Canna-Measure™ records and with AI technology reports the symptom improvement. This data can be recorded for up to **repeate** measures.
- The results are **perceives (SP)** as positively improving the patients symptoms if the she or he records a 15% improvement and this data is also used for the Canna-Meter™ and objective data.

Sales Process – Slide 6

Revenue Streams – Slide 7

<p>App</p> <ul style="list-style-type: none"> ● Mobile ● Website <p>CBD Products</p> <ul style="list-style-type: none"> ● Retail ● Wholesale <p>CEU Classes</p> <ul style="list-style-type: none"> ● Events ● Online 	<p>Ecommerce Website</p> <ul style="list-style-type: none"> ● Retail <p>Wholesale</p> <p>SaaS</p> <ul style="list-style-type: none"> ● Physicians ● Dispensaries ● Retail
--	---

Target Markets

22,846,867

Market Size

Approximate total Market Size # of People for NJ, NY, PA, and FL

513,000

Current medical marijuana card holders and medical marijuana users by our target states.

9,252,628

Patients currently on a consistent opioid regimen for chronic pain and other conditions.

12,313,725

Patients with chronic conditions or symptoms that are not being managed with other treatments but that can be alleviated with the use of medical cannabis.

767,514

Patients in drug addiction treatment programs that can wean off drugs with the help of cannabis

Competition – Slide 8

Competitive Research

- | | |
|--------------------------|----------------|
| 1. Cannabis Strain Guide | 7. Leafly |
| 2. CannaDx | 8. Releaf |
| 3. CBD Greens | 9. Strainprint |
| 4. Daily Bonfire | 10. WeedPro |
| 5. Herb | 11. ZenMD |
| 6. HiGrade | |

Cannabis Strain Guide

- The Cannabis Strain Guide developed by Denovo Studios LLC is your go-to app for cannabis strain information. You can search through hundreds of strains and save personalized notes and favorite strains all in one place for easy reference later. The app includes full strain descriptions, history, and reviews from cannabis experts and real users. [Apple App Store LINK](#)

CannaDx

- The CannaDx App lets you find a cannabis strain that works for you based on its chemical profile. Start using our cutting-edge CannaDx application to discover how the Total Canna Profiles of different cannabis strains influence patient ailments and feelings. Use the personal tracking journal to personalize the data to how it makes YOU feel and save it to your personalized smart Algorithm. Track your feelings and home in on the perfect ratios of Cannabinoids and Terpenes that work for you. Use our CannaDx recommendation engine to specify exactly what you want to relieve. Narrow down your search from the most popular strains in the world by ailment and possible associated feelings/side effects. Discover the perfect chemical profile you need. Then locate that strain profile at a local dispensary near you using our mapping feature. [Apple App Store Link](#)

CBD Greens

- The CBD Greens Cannabidiol Guide App developed by Green Market Technology Inc. is a leading resource for the community on Cannabidiol education and information. It's a great place to find everything from products, CBD training, laws, and regulations, to educational videos on what medication of CBD might be best for your personal needs. [Apple App Store LINK](#)

Daily Bonfire

- The Daily Bonfire App developed by HelloMD is the first cannabis live trivia game designed to incentivize users to play an active role in combating today's illicit retail marketplace and to further promote the destigmatization of cannabis, both used recreationally and medicinally. [Apple App Store LINK](#)
- HelloMD is a digital healthcare platform for the cannabis industry. Patients use the HelloMD service to connect with a doctor, get a medical cannabis recommendation over live video (Telehealth), and gain seamless entry to thousands of cannabis products, dispensaries and advice on medicinal efficacy. <https://hellomd.com/pages/daily-bonfire>

Herb

- Herb is a website and mobile app that connects people with great local stores, brands, and cannabis. Herb is an immersive technology platform that simplifies cannabis from discovery to purchase. The community has 14 million cannabis enthusiasts. Each month Herb reaches 265 million video viewers and inspire 85 million engagements. <https://herb.co/app>

HiGrade

- The HiGrade App provides instant cannabis testing straight from your smartphone. Check your bud's THC level, know its quality, or simply be more mindful about the product you consume. HiGrade fuses artificial intelligence algorithms with analytical chemistry to decipher the quality of cannabis flowers from smartphone images. www.gethigrade.com/about.php

Leafly

- The Leafly App is the world's cannabis resource to learn about weed and to discover and discover your ideal weed strains, tinctures, topicals, concentrates, or pot edibles based on hundreds of thousands of user-submitted reviews, desired effects, aromas, flavors, recommended strain lists, and availability at nearby weed dispensaries or retail stores. Using our integrated weed maps, you can find marijuana and CBD products and medical marijuana doctors. [Apple App Store LINK](#)

Releaf

- The Releaf App allows users to personally track their own healthcare when it comes to medical cannabis and CBD use. Releaf is a free tool to help you track, learn from, and improve your use of cannabis & CBD. Learn which products and administration types are most effective for your use and treatment. [Apple App Store LINK](#)

Strainprint

- The Strainprint App functions as a data-collection tool that allows users to enter the symptoms they are experiencing, the cannabis strains they are using, and then track. Founded in Toronto Canada in 2016, Strainprint™ Technologies is the leader in demand-side cannabis data and analytics. Strainprint™ was created by patients for patients with a mission to advance the scientific understanding of cannabis and its legitimization as a mainstream therapy. We support cannabis patients, practitioners, industry and government with the most sophisticated and easy to use digital technologies for responsible cannabis use and global research. Strainprint™ is privacy compliant, military-grade encrypted, and all patient data is completely anonymized and at rest in Canada. [Apple App Store LINK](#)

WeedPro: Cannabis Strain Guide

- WeedPro is your go-to app for cannabis strain information. You can search through thousands of strains and save personalized notes and favorite strains all in one place for easy reference later. The

app includes full strain descriptions, history, and reviews from cannabis experts and real users.

[Apple App Store LINK](#)

ZenMD

- The ZenMD App lets you meet face-to-face with a licensed doctor using online Telehealth technology to discuss your medical condition. See a doctor from the comfort of your home - it's 100% online! [Apple App Store LINK](#)

Competitive Differentiator – Slide 9

Multiple revenue streams

- MyCureAll SaaS Platform
- MyCureAll CBD Products
- CEU Classes
- Ecommerce Website

Proprietary Technology

Standardized Set of Protocols

- Providing doctors with a first-ever standardized set of protocols when it comes to prescribing medical cannabis by detailing all cannabis strains with respect to the conditions they treat.

Streamline the Recommendation Process

- Connecting patients to doctors and dispensaries to streamline the recommendation process for medical cannabis.

App Features

- Self and Recommender Admin Assessments: PHQ-9; RODS; GAD; PTSD
- Reminder SMS or email for Recommender and Dispensary
- Puff Journey: Develop Personalized Treatment Plans
- Store 5 PDF Files for Medical and Benefits
- Find a dispensary with GPS
- Create Insurance Claim: Puff Journey Results
- View Patients Assessments and Puff Journey Results
- Register with Multiple offices
- Validations Protocol
- View ICD 10 with Conditions
- View insurance Types
- List and Schedule Availability
- Puff Journey - Treatment Plan: Subjective and Objective Results
- “Canna-Meter ” tool: Informed Recommendation Demonstration
- Verification Process
- Search Patient Population by State, Zip Code, Symptom or Condition with ICD 10 Codes

Client Retention – Slide 10

Management – Slide 11

Management Team and Advisors

- Elaine K. Richer, RPH CEO - Licensed pharmacist in New Jersey and Florida for over 20 years.
- Jacques Nir, COO 24 years' experience in New York State Healthcare Systems
- Daniel Milham, MIS Director
- Dr. Cynthia C Chirwa, Medical Advisor
- Dr. Mark Duckshtine, Medical Board Member
- Peter Thurlow, Legal Board Member
- Karen Berger, PharmD, Medical Writer

Elaine K. Richer, RPH CEO

Ms. Richer is a highly seasoned Pharmacist and healthcare professional that has held leadership roles in three Fortune 500 companies that include Rite Aid, Walgreens, and CVS Caremark. Ms. Richer is a graduate of Long Island University School of Pharmacy and has been a licensed pharmacist in New Jersey and Florida for over 20 years.

Ms. Richer wants to make our society a better place, and her goal is to decrease opioid overdoses, decrease deaths from suicides and overdoses, reunite families suffering due to drug addiction, and help patients achieve the most effective pain control.

Ms. Richer is dedicated to providing quality patient care and ensuring improved clinical outcomes. In her 20-plus years as a pharmacist, she has seen tens of thousands of patients for dozens of different conditions. As a pharmacist, she always strives to help patients, make their lives happier, healthier, and ease their burdens. Addiction is a tough illness and she feels honored to help patients on their road to recovery. At MyCureAll, her mission is to optimize innovation to treat pain properly, while preventing addiction at its core, and ensure improved clinical outcomes.

She has successfully trained and managed diverse teams of pharmacists and has in-depth experience in all aspects of the Pharmacy benefit managers (PBM) industry that are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers, and other payers.

- Pharmacy benefit managers have stepped in to help manage prescription claims for insurers when coverage expanded under the Affordable Care Act and with the creation of the Medicare Part D program.
- PBMs handle way more than claims processing. They help with formulary management, drug utilization review, determining which pharmacies are in-network and how much those pharmacies will receive in reimbursement.
- Their expanded role in the drug supply chain has made them valuable partners for top insurers.

Jacques Nir, LCSW, Chief Operations Officer

Mr. Nir is a graduate of Columbia University School of Social Work, Adjunct Professor at Columbia University School of Social Work and for the past 12 years been the Director of Substance Abuse outpatient programs at the redesigned New York State OASAS (Office of Alcoholism and Substance Abuse Services) inpatient element treatment facilities. Mr. Nir has provided quality care as a social worker for 24 years and been responsible for multi-million-dollar budgets with OASAS and the New York Office of Mental Health.

The Office of Addiction Services and Supports (OASAS) oversees one of the nation's largest addiction services systems with approximately 1,600 prevention, treatment and recovery programs. OASAS chemical

dependence treatment programs have an average daily enrollment of nearly 100,000 people and serve approximately 234,000 individuals every year. This includes the direct operation of 12 Addiction Treatment Centers, which serve around 8,000 persons per year. OASAS is the single designated state agency responsible for the coordination of state-federal relations in the area of addiction services. Our mission is to improve the lives of New Yorkers by leading a comprehensive premier system of addiction services for prevention, treatment, and recovery.

Mr. Nir has devoted his career to the public sector of social work and has worked with community-based programs for over 20 years. The evidence indicates and supports medicinal cannabis and CBD as a MAT (medication assisted treatment) protocol for both the OASAS (Office of Alcoholism and Substance Abuse Services) and OMH (Office of Mental Health). Our program will save lives, increase compliance with recovery, and reduce Medicaid expenditures. CBD and medicinal cannabis, administered with continuing care, will prevent relapse from opiates and promote psychiatric treatment. These substances need to be covered by an individual's insurance policy. As the data proves, we will save lives and provide a safer, alternative form of medical treatment to reduce recidivism and redundant services.

[Operations- Slide 12](#)

[5-Year Projection – Slide 13](#)

[Capital Needs and Uses – Slide 14](#)

[Exit Strategy – Slide 15](#)

Acquisition:

Cannabis – MSO Operators, CBD

CPG Companies

Pharma - GW Pfizer, Merck, AstraZeneca

Technology

Most likely exit option for companies:

- ✓ Name potential companies (any unique relationship with them)
- ✓ Name type/category of companies that could acquire you?
- ✓ Why would they acquire you? How do you fit in their category?
- ✓ Why won't they try to build it themselves?

Financial Buyer:

Will your company generate excess cash flow that could make it attractive to financial buyers to generate a return?

IPO:

Least likely exit for a company, but a probability. Preferred strategy only when no buyer can afford the valuation of your company.